GLP-1 & Incretin Science

Why a Drug Works Less Well Than Its Trial Said

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

Efficacy is what a treatment achieves under trial conditions with selected participants and monitored adherence. Effectiveness is what it achieves in routine care. The second is reliably smaller, and the reasons are structural rather than mysterious.

Key facts

Efficacy
Trial conditions, selected participants
Effectiveness
Routine care, everyone
Direction
Effectiveness is reliably lower
Main causes
Selection, monitoring, persistence
Formalised by
Efficacy vs treatment-policy estimand
Measured by
Cohort studies, target trial emulation

Selection is the first cause

Trials exclude people. Those with competing conditions, on interfering medications, unlikely to attend visits, or unable to consent are screened out. The resulting population is healthier and more able to comply than the population who will eventually receive the drug, and the trial result belongs to the group that was studied.

Monitoring is the second

Trial participants are seen regularly, reminded, and have adverse effects managed promptly by people whose job is to keep them in the study. That support is itself an intervention. Removing it does not merely remove convenience; it removes a mechanism that was helping produce the result.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

Persistence is the third and largest

The most efficacious treatment achieves nothing in someone who has stopped taking it. Where real-world persistence is substantially lower than trial completion, the population-level effect falls proportionately, and for a chronic condition where stopping reverses the benefit, this dominates the other causes.

How the gap is measured

Observational data analysed carefully, which is where target trial emulation earns its place. It applies trial-like design discipline to routine records, producing an estimate of what happens in practice while removing the analytical biases that would otherwise make such comparisons uninterpretable.

Why the gap is not evidence of a bad trial

A randomised trial is designed to establish whether a drug can work, under conditions favourable enough to detect an effect if one exists. That is a necessary first question, and answering it well requires exactly the control that limits generalisability. Efficacy and effectiveness are two questions, and it is reasonable to answer them in that order.

How to read any headline figure

Ask which question it answers. A 20% reduction from a randomised trial describes selected participants under monitoring, on the efficacy estimand, among those who continued. Every one of those qualifiers moves the number, and a figure travelling without them is describing a situation almost nobody is in.

Quick reference

EfficacyEffectiveness
PopulationSelectedEveryone treated
SupportTrial monitoringRoutine care
AdherenceHigh, encouragedVariable
Typical sourceRandomised trialCohort, emulation

Frequently asked questions

Why is effectiveness lower than efficacy?

Selection, trial monitoring and real-world persistence. The first two make trial populations perform better; the third removes benefit entirely for those who stop.

Does the gap mean the trial was flawed?

No. A trial establishes whether a drug can work, which requires control that necessarily limits generalisability. They are two questions asked in order.

How is effectiveness measured?

Observational data analysed with trial-like discipline, with target trial emulation being the method built for exactly this.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.